Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned

International Journal for Parasitology(2020)

Cited 0|Views7
No score
Abstract
•BKIs that target CDPK1 in apicomplexan parasites with a glycine gatekeeper are promising new therapeutics.•Numerous challenges have shaped our selection of pre-clinical BKI candidates.•These include chirality, hERG, teratogenicity, cardiovascular, GI, and toxicity issues, and poor efficacy due to PK/PD.
More
Translated text
Key words
Apicomplexa,Bumped Kinase Inhibitor,Calcium-dependent Protein Kinases,Gatekeeper,Cryptosporidium,Toxoplasma,Neospora,Sarcocystis
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined